The Ramat Gan-based Medasense Biometrics, which has developed technology for pain-response monitoring, has raised $18M in a Series C round, the company announced Tuesday.
Medasense's NOL (nociception level) technology uses a multi-parametric sensor platform and advanced AI algorithms to convert complicated data into a patient's "Signature of Pain." This allows clinicians to control pain, avoid overdose, and eliminate doubt. The technology is currently in use in operating rooms and critical care settings, where patients are under anesthesia and unable to communicate.
The company has also been active in implementing its technology for COVID patients on ventilators.
